Genmab's Epcoritamab Combination Therapy Approved
Company Announcement
Genmab A/S (NASDAQ: GMAB) has achieved an important milestone with the FDA's approval of Epcoritamab, marketed as EPKINLY®, combined with rituximab and lenalidomide, a trio set to offer hope to adults suffering from relapsed or refractory follicular lymphoma (R/R FL).
Pivotal Phase 3 Study Results
The decision from the FDA stems from compelling evidence presented in the Phase 3 EPCORE FL-1 study. Here, the EPKINLY combination exhibited a significant push towards improved patient outcomes. The therapy yielded a striking 79% reduction in the risk of disease progression or death when compared to the standard of care.
Median progression-free survival (PFS) for those receiving EPKINLY and R2 has not yet been reached, a promising sign contrasting with the 11.2 months reported for the traditional treatment. Remarkably, 89% of the treated patients responded favorably to this regimen, with a 74% complete response rate, emphasizing its potency in the therapeutic landscape.
The Importance of New Therapeutics
These outcomes highlight a critical shift in treating follicular lymphoma, a notoriously challenging cancer to manage due to its recurrent nature. Dr. Lorenzo Falchi, a leading lymphoma specialist, highlighted the significance of the data, underscoring EPKINLY + R2 as a potential new standard of care.
Understanding Follicular Lymphoma
Follicular lymphoma is a slow-growing form of non-Hodgkin lymphoma, which impacts around 15,000 new patients each year. Despite being deemed incurable with standard therapies, EPKINLY's approval indicates a breakthrough in managing this persistent disease.
This novel bispecific therapy can be administered in various medical settings, allowing better patient access to treatment close to home, a crucial factor for many undergoing cancer therapies.
Potential Side Effects and Safety Profile
While the approval brings hope, it's essential for patients and their caregivers to understand the potential side effects. The study revealed that common adverse reactions included fatigue, injection site reactions, and respiratory tract infections, with 24% of patients experiencing cytokine release syndrome (CRS).
Patients will be closely monitored for these adverse effects, especially during their initial doses to ensure their safety and well-being throughout the treatment process.
Genmab's Commitment to Patients
Genmab is steadfast in its commitment to improving the lives of patients battling cancer. Through programs like MyNavCare Patient Support™, they provide resources to navigate treatment journeys, ensuring that patients have the support necessary to access their medications effectively.
Future Aspirations
EPKINLY + R2 not only presents a significant step forward for current patients but also reflects Genmab's dedication to exploring its potential across a range of hematologic malignancies. Ongoing clinical trials are evaluating the efficacy of Epcoritamab in various combinations and settings, showcasing the company's innovative spirit.
Genmab, established in 1999, is targeted toward revolutionizing cancer treatment. Their vision includes expanding international regulatory approvals for their therapies, allowing them to reach patients worldwide.
Frequently Asked Questions
What is EPKINLY?
EPKINLY is a bispecific antibody approved for treating relapsed or refractory follicular lymphoma, administered in combination with rituximab and lenalidomide.
How does EPKINLY work?
EPKINLY works by directing the body's immune system to target and eliminate cancerous B cells while avoiding chemotherapy.
What were the results of the EPCORE FL-1 trial?
The trial found that EPKINLY + R2 led to significantly improved patient outcomes, including high overall response and complete response rates.
What are the common side effects of EPKINLY?
Common side effects include rash, fatigue, upper respiratory infections, and potential symptoms of cytokine release syndrome.
How can patients access support for their treatment?
Patients can benefit from Genmab's MyNavCare Patient Support™ for guidance and resources throughout their treatment journey.
